Cambridge Healthtech Institute 第2届

Strategic Alliance Management Congress Europe

透过合作及伙伴关系推动制药产业进步

2018年12月3日~5日


Strategic Alliance Management Europe已迈入第2届,来自联盟管理、业务开发、专案管理、技术转移、授权等业务的各类组织主管将齐聚一堂,在相互交流的同时、讨论案例、思考推动成功合作的要素。会期中,各领域领导专家将分享推动联盟管理方法的策略性见解、有效实证工具及方法、未来展望等。

Final Agenda

Monday 3 December 2018

11:00 Registration


KEYNOTE SESSION

13:55 Organizer's Welcome and Chairperson’s Opening Remarks

Kaitlin Kelleher, Conference Director, Cambridge Healthtech Institute
Dana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

14:00 Welcome Progress with Observations on Partnering

Hughes_J-DanaDana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

As we gather for another year of discussions and the sharing of stories from our organizations, we wanted to start with some framing on the current state of the marketplace. This short presentation will set the stage for the conference and prepare everyone for a deeper interactive discussion at the end of the day in the form of the “Big Pharma-Biotech Back-and-Forth: Tell Me What’s Wrong, and How I Can Help!”.

14:15 Diverse Models for a Diverse Portfolio: External and Internal Governance for Strategic Alliances

Stilz_UliUli Stilz, PhD, Vice President, Alliances & Innovation Outreach, Novo Nordisk

Experiences and specific learnings from different industry-academia collaboration models Novo Nordisk has been using to foster biomedical innovation at the interface between academic and industrial research will be discussed. Each collaboration model has been designed to address distinct business needs. Alignment on strategic objectives and business needs, anchoring within business functions, and strong alliance management support have been instrumental to create value for the collaborating parties.

14:45 CO-PRESENTATION: Strategic Alliances and Brexit

Ambwani_KaranKaran Ambwani, Head of Strategic Projects, EU & International Market, Teva


Tyssier_ErickErick Tyssier, Head, Government Affairs Europe, Teva

We will discuss managing the impact of Brexit on European-wide strategic alliances.


15:15 Pharma-Biotech Back-and-Forth: Tell Me What’s Wrong, and How I Can Help!

Hughes_J-DanaDana Hughes, Vice President & Global Head, Integration and Alliance Management, Worldwide Business Development Group, Pfizer

Join a frank, open (and ideally fun) ice-breaking exercise meant to involve all conference participants on those real issues that time and again rise in partnerships between large and small companies. Often each side is unaware of how to improve alignment with their partner. This session provides attendees with a safe means to expose these frequent pain-points and hear the perspective of “the other side.” If successful we will have the opportunity to discuss potential practices to alleviate common issues and ideate on more difficult issues.

16:00 Welcome Reception

17:00 End of Day


Tuesday 4 December 2018

7:30 Morning Coffee

THE EVOLUTION OF ALLIANCE MANAGEMENT

8:25 Chairperson’s Remarks

Uli Stilz, PhD, Vice President, Alliances & Innovation Outreach, Novo Nordisk

8:30 Evolving Alliance Management Practices at Boehringer Ingelheim

Walke_StefanStefan Walke, PhD, Head, Contracts and Alliance Management (CAM), Europe, Boehringer Ingelheim

This talk will discuss how Boehringer Ingelheim is moving from a project alliance management model to a portfolio alliance management model. We will address how to assess internal teams, split resources, and determine how much alliance management is needed per project.


9:00 J&J Innovation and the Evolving Alliance Management Role

Benz_PatrickPatrick Benz, PhD, Senior Director Alliance Management, Janssen Business Development (JBD), Janssen

Johnson & Johnson Innovation is comprised of a family of complementary teams that bring meaningful solutions and flexible approaches to support collaboration. From incubation facilities to early-stage investing – from venture funding to acquisition, our teams offer partners a full range of capabilities. Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships. Such long-term collaborations need an appropriate Alliance Management Structure to meet the high expectations.

9:30 Evolution of Alliance and Integration Management at UCB: Key Aspects and Lessons Learned

Boyhan_AngelaAngela Boyhan, PhD, Vice President, Head of Alliance & Integration Management, Alliance Management, UCB Biopharma SPRL

The recent creation of Corporate Strategy & Development ( CS&D) organization within UCB ensures a holistic approach to partnerships and acquisitions, improving external and internal collaboration and knowledge sharing. The position of Alliance & Integration Management within CS&D alongside Scouting, Business Development and M&A strengthens our connections and complement the end to end partnering process, allow for aligned partnership management, thus increasing our impact in maximizing the value on our Alliances for partners, patients and UCB. We share the evolution of our approach to Alliance and Integration management at UCB and our learnings during this period.

10:00 Coffee Break

DEVELOPING THE ALLIANCE MANAGEMENT FUNCTION

10:45 Alliance Management Capability Development

Huwe_ChristophChristoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals

New developments in the healthcare industry will likely increase the number and complexity of alliances. This will require higher alliance capability levels and a broader distribution of alliance skills throughout the organizations involved. Using Bayer Pharmaceuticals as an example the presentation will highlight this development and illustrate how to manage it using specialized alliance management core groups, an alliance community effort and alliance team qualification beyond the core groups.

11:15 Embedding Alliance Management Capabilities in a Fast-Growing Biotech Organization

Witte_FlorianFlorian Witte, Director, Alliance Management, Pieris Pharmaceuticals

Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. In the most recent past, Pieris has entered into three major strategic alliances in the field of respiratory and immuno-oncology to accelerate its transformation into a fully-integrated R&D and commercial organization. Full commitment and investment in alliance business as key value driver for the future consequentially comes with establishment of a dedicated alliance management function and with changing operational, structural and cultural aspects. The talk will describe the overall alliance management concept at Pieris, implementation of tools and techniques, change management as well as first steps in the long-term vision of becoming a “partner of choice.”

11:45 Sharing Best Practices to Enable a Successful AM Function

Celine Carlet, Director, Alliance Management & Business Development, Global Operations, Ferring Pharmaceuticals

The rise of AM activities is connected to the increasing need of the pharma industry to broadly collaborate to increase the speed of development, reduce costs and gain access to new markets while limiting risk exposure. This presentation will be on tips on how to build an effective alliance management function that meets both internal and external expectations and needs regarding successful execution of deals

12:15 Alliance Management Community at UCB: 7 Key Success Factors

Vanderavero_CecileCécile Vanderavero, Head, Alliance Management Community, Alliance and Integration Management Corporate Strategy & Development, UCB Biopharma

With hundreds of colleagues involved – in one way or another – in managing an external collaborations or partnerships, and only a few of them being full-time dedicated alliance managers (AM), the set up and management of an AM community has become critical in the development of the partnering capability across UCB. In this presentation, we will explain how the AM community was set up and how it is currently managed, what the main achievements are so far, and what the key success factors have been.

12:45 Sponsored Luncheon Presentation (Opportunity Available)

CASE STUDIES IN ALLIANCE MANAGEMENT

14:25 Chairperson’s Remarks

Christoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals

14:30 The CRUK MedImmune Alliance Laboratory: An Innovative Alliance Model

Little_JulieJulie Little, Strategic Alliance Executive, Commercial Partnerships, Cancer Research UK

Our standalone laboratory brings together the charity Cancer Research UK and its expertise in cancer biology, the novel biology of academic scientists, and the world-class antibody engineering technology of MedImmune, the global biologics research and development arm of AstraZeneca. In a very collaborative environment, we work closely with academic scientists to access novel biology and targets to help translate their discoveries into cancer patient benefit. We will describe how the laboratory came about and how it operates, the value of such an alliance as well as lessons learnt now that the laboratory has been in existence for over 3 years.

15:15 CO-PRESENTATION: A Development Partnership – Palatin Technologies and AMAG Pharmaceuticals

Svahnqvist_HeleneHélène Svahnqvist, Senior Director, Alliance Management, AMAG Pharmaceuticals, Inc.

Rob Jordan, Vice President, Clinical Operations and Program Management/Alliance Management, Palatin

Managing through the details: How Alliance Management operationalized the license agreement and adapted throughout the partnership to ensure collaborative joint development.


16:00 Sponsored Presentation (Opportunity Available)

16:30 Breakout Discussion Groups


Table 1: Alliance Management at the Forefront of Deal Making
Moderator: Colette Mitchem, MBA, Associate Director, Corporate and Business Development, Norgine Ltd.

  • At what point should Alliance Management get involved in the deal making process?
  • What contributions can an alliance manager make to the negotiation process?
  • How would a partner perceive Alliance Management at the table? What message would that deliver about your company’s approach to partnership?
  • What steps are required to gain alignment in your own organization about the role of Alliance Management in the deal making process?

Table 2: Alliance Launch
Moderator: Neil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

  • How, if at all, does your organization employ a systematic approach to launch alliances?
  • What are the initial challenges, necessities and opportunities during an alliance launch?

Table 3: Introducing Alliance Management to a Growing Biotech Company
Moderator: Florian Witte, Director, Alliance Management, Pieris Pharmaceuticals

  • Which Alliance Management skills and tools do companies need to possess?
  • How can organizations develop a culture of open innovation?
  • What are the ways to create value and share it among stakeholders involved?
  • How do you get CEO and senior management engagement?

Table 4: The Bigger Picture: The Alliance Lifecycle – Managing Change and Termination
Moderator TBA

  • How can turnover positively or negatively impact an alliance?
  • What measures can be taken to ensure that turnover has little impact on the alliance relationships, goals, and achievements?
  • How can planning and communication successfully manage the end of the alliance lifecycle while preserving value and relationship?

Table 5: Collaborative Culture in Alliance Teams
Moderators: Christoph Huwe, PhD, CSAP, Strategic Alliance Manager Therapeutics, Global External Innovation & Alliances, Bayer AG Pharmaceuticals
Yuri Khakhanov, PhD, Director for Projects Development, Energy Efficiency Cluster, Skolkovo Innovation Center

  • How to prepare good collaboration within an alliance team
  • How to analyze the current level of collaboration
  • How to improve the collaborative behavior within a team

18:00 End of Day

Wednesday 5 December 2018

7:30 Morning Coffee

MAXIMIZING COLLABORATION EFFORTS WITH BIOTECH
AND NON-INDUSTRY PARTNERS

8:25 Chairperson’s Remarks

Neil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

8:30 Alliance Management: Maximizing Collaboration Efforts

Henrik Sorensen, PhD, Head, Alliance & Portfolio Management, Immunocore, Ltd.

This talk will address how Immunocore is maximizing collaboration efforts from deal-making through project management.

9:00 Collaborative Themed Drug Discovery Alliances at CRUK: The Art of Harmonizing “Herding Cats” and “Dancing with The Devil”

Jones_NeilNeil Jones, PhD, Senior Group Leader, Discovery Bioscience, Cancer Research UK Therapeutic Discovery Laboratories

CRUK Therapeutic Discovery Laboratories brings together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients. The talk will feature examples from our innovative drug discovery alliances and some of the tools and techniques we use to enable these collaborations to deliver their full potential.

9:30 A Portfolio Approach to Collaborations: Managing Alliance Networks in High-Tech

Khakhanov_YuriYuri Khakhanov, PhD, Director for Projects Development, Energy Efficiency Cluster, Skolkovo Innovation Center

Collaborative innovation has transformed the high-tech sector worldwide. Ecosystems emerged throughout the industry as many new alliance-based businesses were created. A portfolio approach to collaborations should be introduced to manage ecosystems where organizations require new alliance management tools and business models. The presentation discusses: portfolio approach to create innovative ecosystem – common success factors; synergy achieved in clusters of high-tech companies; portfolio optimization to provide maximum value to all partners.

10:00 Coffee Break

EXAMINING DIVESTMENTS AND OUT-LICENSING

10:45 A Divestment Playbook: Tools and Lessons Learned from a Transition Lead

Cavalli_ElenaElena Cavalli, CSAP, Director - Alliance Management, Business Development, Astellas Pharma Europe

With the rapidly evolving external pressures in the pharmaceutical world, businesses need to have the capability to swiftly and efficiently divest the non-core assets to help divert resources into the priority products within the portfolio. This presentation will take a practical look at the value that the Alliance Management Professional can bring to the post-deal divestment management.

11:15 The Out-Licensing Alliance Lifecycle: From the Cradle to the Grave

Mitchem_ColetteColette Mitchem, Associate Director, Corporate and Business Development, Norgine Ltd.

This talk will discuss the lifecycle of out-licensing alliances, from establishing a relationship to launching a product to managing an exit.


CLOSING EXERCISE

11:45 Closing Exercise: Breakout Discussion Report Out

Table Moderators

12:40 Closing Remarks

Kaitlin Kelleher, Conference Director, Cambridge Healthtech Institute

12:45 End of Congress

* 活动内容有可能不事先告知作更动及调整。